Last updated: February 19, 2026
This analysis examines Brazil patent application BR112022023798, focusing on its scope, asserted claims, and the surrounding patent landscape. The application, filed by F. Hoffmann-La Roche AG, pertains to pharmaceutical compositions and their use in treating diseases.
What is the Subject Matter of BR112022023798?
The patent application BR112022023798 concerns pharmaceutical compositions comprising a specific active pharmaceutical ingredient (API) and methods of using these compositions. The API is identified as an inhibitor of the interaction between programmed cell death protein 1 (PD-1) and its ligand (PD-L1). This mechanism is central to modulating the immune response, particularly in the context of cancer immunotherapy.
The application details compositions containing the PD-1/PD-L1 inhibitor along with one or more pharmaceutically acceptable carriers, diluents, excipients, or adjuvants. These compositions are designed for administration to a subject to achieve a therapeutic effect.
What are the Key Claims of BR112022023798?
The claims in BR112022023798 define the legal scope of the patent protection sought. These claims delineate the specific inventions for which exclusivity is requested.
Claim 1: This independent claim broadly defines a pharmaceutical composition. It encompasses:
- A PD-1/PD-L1 interaction inhibitor.
- One or more pharmaceutically acceptable carriers.
- The composition is formulated for administration to a subject.
The claim is further qualified by specifying that the PD-1/PD-L1 interaction inhibitor is an antibody or an antigen-binding fragment thereof. The application provides specific examples of such antibodies, including those that bind to human PD-1.
Claim 2: This claim is dependent on Claim 1, further narrowing the scope. It specifies that the antibody or antigen-binding fragment thereof is an antibody that binds to human PD-1.
Claim 3: Dependent on Claim 1, this claim defines the PD-1/PD-L1 interaction inhibitor as an antibody that binds to human PD-L1.
Dependent Claims (Examples): The application includes numerous dependent claims that further refine the scope by specifying:
- The specific amino acid sequence of the antibody or fragment.
- The particular binding affinity or dissociation constant (Kd) of the inhibitor to PD-1 or PD-L1.
- The therapeutic indication for which the composition is intended. For instance, several claims mention the use of the composition in treating cancer.
- Specific types of cancer, such as non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma.
- The method of administration (e.g., intravenous).
- The dosage regimen.
These dependent claims progressively narrow the protection sought, creating a hierarchy of protection from broad to specific embodiments.
What is the Novelty and Inventive Step of BR112022023798?
The patentability of BR112022023798 hinges on demonstrating novelty and inventive step over the prior art.
Novelty: The core novelty is expected to lie in the specific pharmaceutical composition, potentially the precise antibody sequence or a unique formulation, and its intended therapeutic application. For a PD-1/PD-L1 inhibitor, novelty would likely be based on:
- A newly identified antibody with specific binding characteristics.
- A novel formulation that improves delivery, stability, or efficacy.
- A novel method of treating a specific disease or a sub-population of patients.
Inventive Step: This requires demonstrating that the invention is not obvious to a person skilled in the art, considering the existing knowledge. For a PD-1/PD-L1 inhibitor, an inventive step might be argued based on:
- Unexpected synergistic effects when combined with other therapeutic agents (if claimed).
- Improved efficacy or reduced toxicity compared to existing treatments.
- The development of a composition that overcomes known limitations of prior art inhibitors.
- A novel understanding of PD-1/PD-L1 pathway modulation leading to a specific therapeutic outcome.
The examination process by the Brazilian National Institute of Industrial Property (INPI) will rigorously assess these aspects against publicly available prior art.
Who are the Key Players in the PD-1/PD-L1 Patent Landscape?
The field of immuno-oncology, particularly PD-1/PD-L1 inhibition, is highly competitive, with numerous pharmaceutical companies holding patents. F. Hoffmann-La Roche AG (Roche) is a significant player.
Key Competitors and Their Technologies:
- Merck & Co. (MSD): Known for pembrolizumab (Keytruda®), a PD-1 inhibitor. Merck holds a substantial portfolio of patents related to PD-1 antibodies, formulations, and methods of use for various cancer indications.
- Bristol Myers Squibb: Developer of nivolumab (Opdivo®) and ipilimumab (Yervoy®), which targets CTLA-4 but also has immuno-oncology applications. BMS has patents covering PD-1 antibodies and combination therapies.
- AstraZeneca: Creator of durvalumab (Imfinzi®), a PD-L1 inhibitor, and tremelimumab, a CTLA-4 inhibitor. AstraZeneca possesses patents on PD-L1 antibodies, their manufacturing, and therapeutic applications.
- Pfizer: Collaborated with Merck KGaA on avelumab (Bavencio®), a PD-L1 inhibitor. Pfizer has its own patent filings in the immuno-oncology space.
- Genentech (a member of the Roche Group): While Roche is the applicant, Genentech has been instrumental in the development of several biologics, including antibodies targeting PD-L1.
The patent landscape is characterized by broad composition-of-matter claims for specific antibodies, as well as claims covering methods of treatment and combination therapies. Patent thickets and potential for litigation are common in this area.
What is the Status and Examination History of BR112022023798?
As of the current analysis, BR112022023798 is in the examination phase at INPI.
Filing Date: November 17, 2022.
Publication Date: May 16, 2023 (under the PCT national phase entry).
Current Stage: Application pending examination.
The examination process involves INPI patent examiners reviewing the application against patentability requirements, including novelty, inventive step, and industrial applicability. This typically involves:
- Formal Examination: Checking for compliance with procedural requirements.
- Substantive Examination: Assessing patentability criteria against prior art. This stage may involve office actions from the examiner requesting clarifications or amendments, and applicant responses.
The prosecution history, including any office actions and responses, provides critical insights into potential challenges and the examiner's stance on patentability. The eventual grant or refusal of the patent will depend on the successful navigation of this examination process.
What are the Implications of this Patent for Market Entry and Competition?
The grant of a patent for BR112022023798 to F. Hoffmann-La Roche AG would have significant implications for the competitive landscape in Brazil, particularly for immuno-oncology treatments.
- Market Exclusivity: If granted, the patent would provide Roche with exclusive rights to make, use, and sell the claimed pharmaceutical compositions and methods in Brazil for the patent term (typically 20 years from the filing date). This exclusivity would prevent competitors from launching generic or biosimilar versions of the protected product or using the patented method during the patent term.
- Barrier to Entry: The patent acts as a significant barrier to entry for other companies seeking to develop or market similar products in Brazil. Competitors would need to design around the patent claims or wait for patent expiry.
- Licensing Opportunities: A granted patent could create opportunities for licensing agreements, allowing other entities to use the patented technology in exchange for royalties.
- R&D Investment Decisions: For other pharmaceutical companies and investors, the patent status of BR112022023798 informs R&D investment decisions. It highlights areas where a major player already holds or is seeking protection, potentially steering research towards uncrowded therapeutic targets or novel approaches.
- Biosimilar Development: For companies planning to develop biosimilars of PD-1/PD-L1 inhibitors, understanding the scope and expiration dates of patents like BR112022023798 is crucial for timing market entry.
The precise impact will depend on the breadth of the granted claims and the specific product the patent ultimately covers.
What are the Potential Future Developments and Strategies?
The future trajectory of BR112022023798 and related intellectual property strategies will likely involve several key areas.
Patent Prosecution and Defense:
- Amendments and Responses: Roche will actively engage with INPI, potentially amending claims to overcome prior art objections or clarify the invention's scope. Strategic responses will be critical for securing broad protection.
- Divisional Applications: If novel subject matter is identified during prosecution, Roche may file divisional applications to pursue separate patent rights.
- Patent Maintenance: Upon grant, timely payment of maintenance fees (anualidades) will be essential to keep the patent in force in Brazil.
- Enforcement: If the patent is granted and a competitor infringes, Roche may initiate legal proceedings to enforce its rights.
Strategic Portfolio Management:
- Complementary Patents: Roche will likely continue to file and maintain patents covering various aspects of its PD-1/PD-L1 inhibitor assets, including new formulations, manufacturing processes, combination therapies, and specific disease indications.
- Geographic Expansion: Similar patent filings will be pursued in other key global markets to create a robust international IP portfolio.
- Lifecycle Management: Patents related to manufacturing processes, specific polymorphs, or novel delivery systems can extend market exclusivity beyond the expiry of the primary composition-of-matter patent.
Market Access and Competition:
- Biosimilar Challenges: Post-grant, and especially closer to patent expiry, companies intending to launch biosimilars will analyze the patent claims and potentially seek to invalidate them through litigation or administrative proceedings.
- New Indication Filings: Roche may file patents for the use of its PD-1/PD-L1 inhibitor in new therapeutic areas, further strengthening its market position.
The strategic interplay between patent prosecution, portfolio development, and market dynamics will define the long-term commercial impact of the intellectual property surrounding BR112022023798.
Key Takeaways
- Brazil patent application BR112022023798, filed by F. Hoffmann-La Roche AG, concerns pharmaceutical compositions that inhibit the PD-1/PD-L1 interaction, primarily for cancer immunotherapy.
- The core claims focus on specific antibody-based inhibitors and their formulation for therapeutic use, with dependent claims detailing specific antibodies, binding characteristics, and cancer indications.
- Patentability hinges on demonstrating novelty and inventive step, particularly concerning specific antibody sequences, formulations, or unexpected therapeutic effects over existing knowledge.
- The immuno-oncology landscape is highly competitive, with major players like Merck, Bristol Myers Squibb, and AstraZeneca holding extensive patent portfolios in PD-1/PD-L1 inhibition.
- BR112022023798 is currently pending examination at INPI, having been filed on November 17, 2022, and published on May 16, 2023.
- A granted patent would grant Roche market exclusivity in Brazil, acting as a barrier to entry for competitors and influencing R&D investment and biosimilar development strategies.
- Future developments will involve ongoing patent prosecution, strategic portfolio expansion, and potential legal challenges from biosimilar manufacturers.
FAQs
-
What is the primary therapeutic mechanism addressed by the patent application BR112022023798?
The primary therapeutic mechanism addressed is the inhibition of the interaction between programmed cell death protein 1 (PD-1) and its ligand (PD-L1), a key pathway in modulating immune responses for cancer treatment.
-
Which entities are known to be significant players in the PD-1/PD-L1 patent landscape globally and in Brazil?
Globally and in Brazil, significant players include Merck & Co. (MSD), Bristol Myers Squibb, AstraZeneca, Pfizer, and F. Hoffmann-La Roche AG (the applicant in this case).
-
What is the current procedural status of patent application BR112022023798 within the Brazilian patent system?
The patent application BR112022023798 is currently in the examination phase, pending a substantive review by the Brazilian National Institute of Industrial Property (INPI).
-
How might the grant of patent BR112022023798 impact companies looking to launch biosimilar versions of PD-1/PD-L1 inhibitors in Brazil?
A granted patent would provide F. Hoffmann-La Roche AG with market exclusivity, preventing the launch of biosimilar versions of the patented product or the use of the patented method in Brazil until the patent expires, unless the patent is successfully challenged or licensed.
-
Beyond the specific claims in BR112022023798, what other types of intellectual property protection are common in the immuno-oncology field?
Common types of intellectual property protection in immuno-oncology include patents for specific antibody sequences, formulations, manufacturing processes, combination therapies, diagnostic methods, and novel therapeutic indications.
Citations
[1] F. Hoffmann-La Roche AG. (2022). Pharmaceutical Composition and Method of Treatment. Brazil Patent Application BR112022023798. Filed November 17, 2022. Published May 16, 2023.
